Being Patient speaks with C-Suite business and biotech leader Wendy Nelson, PhD, about her discovery that she carries two copies of Alzheimer’s genetic biomarker APOE4, a gene variant associated with heightened Alzheimer’s risk, and the way this revelation has changed the way she thinks about brain health. Nelson is currently the chief business officer for a strategic advisory company in the life sciences space and has 25 years of business development, project management, operational, and R&D experience in biotechnology and large pharmaceutical companies, as well as in global CROs. She is also president and founder of the Boston Biotech Forum. She’s an inventor on multiple patents and patent applications and has authored a number of scientific publications.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related